This difference in ILD risk has important implications for clinical management, suggesting that while anti-MDA5-positive patients require vigilant monitoring for lung involvement, anti-TIF1-γ-positive patients might benefit more from a focus on their characteristic features such as severe cutaneous manifestations and chronic disease course. This evidence concerns the gene IFIH1 and interstitial lung disease.